ATCHISON, Kan., March 16, 2017 -- MGP Ingredients, Inc. (Nasdaq:MGPI), a leading supplier of premium distilled spirits and specialty wheat proteins and starches, today announced that it will host an analyst day for institutional investors on Thursday, April 6, 2017, at the company’s facility in Lawrenceburg, Ind. The event will include management presentations and a tour of the facility’s distillery and warehouse operations.
The presentations are expected to begin at approximately 9:30 a.m. EDT and last approximately two hours. A live audio webcast of the management presentations will be available on MGP’s Investor Relations site at www.mgpingredients.com. Presentation slides will be posted to the same site on the day of the event.
About MGP Ingredients, Inc.
MGP is a leading producer and supplier of premium distilled spirits and specialty wheat proteins and starches. Distilled spirits include premium bourbon and rye whiskeys, gins and vodkas, which are carefully crafted through a combination of art and science and backed by over 150 years of experience. The company’s proteins and starches are created in the same manner and provide a host of functional, nutritional and sensory benefits for a wide range of food products. MGP additionally is a top producer of high quality industrial alcohol for use in both food and non-food applications. The company is headquartered in Atchison, Kansas, where distilled alcohol products and food ingredients are produced. Premium spirits are also distilled and matured at the company facility in Lawrenceburg, Indiana. For more information, visit mgpingredients.com.
For More Information Investors & Analysts: Bob Burton 616-233-0500 or [email protected] Media: Greg Manis Corporate Director of Communications 913-360-5440 [email protected]


Hyundai Motor Shares Surge on Nvidia Partnership Speculation
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026
xAI Cash Burn Highlights the High Cost of Competing in Generative AI
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 



